Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells
March 15 2018 - 7:30AM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
therapy to treat cancer, today reported three partial responses
(two confirmed and one to be confirmed), and one stable disease in
the first four patients dosed with NY-ESO SPEAR T-cells in a second
solid tumor: myxoid/ round cell liposarcoma (MRCLS). Patients
tolerated treatment well with cytokine release syndrome (CRS)
managed following standard treatment guidelines. GlaxoSmithKline
plc (LSE:GSK) (NYSE:GSK) exercised its option to exclusively
license the right to research, develop, and commercialize NY‑ESO
SPEAR T-cell therapy program in September 2017. Transition of
this program to GSK is ongoing.
“We are encouraged by the initial responses seen in the first
patients with MRCLS treated with NY-ESO SPEAR T-cells, as it
validates the potential of our platform to treat a broad range of
tumors, including those that are known to be unresponsive to
current immunotherapies,” said Rafael Amado, Adaptimmune’s Chief
Medical Officer. “Although MRCLS is a soft tissue sarcoma which
commonly expresses NY-ESO, there are fundamental differences in its
clinical course, natural history, molecular signature, and
responsiveness to standard treatments that make it distinct from
synovial sarcoma. As we expect data from our other trials with our
wholly owned assets throughout 2018, these results in a second
solid tumor strengthen our conviction that our pipeline of unique
TCRs will be capable of addressing multiple solid tumors.”
More about Soft Tissue Sarcomas:MRCLS and
synovial sarcoma are both considered soft tissue sarcomas. MRCLS is
a type of liposarcoma, characterized by the proliferation of
adipocyte (fat cell) precursors called lipoblasts that have
undergone differentiation arrest. This malignancy arises from a
translocation between chromosomes 12 and 16 resulting in a
fusion protein that blocks adipocyte differentiation and promotes
malignant transformation. Synovial sarcoma is characterized by a
different chromosomal translocation involving the X chromosome
and chromosome 18 and, unlike the known immature fat cell cellular
origin of MRCLS, the cell of origin for synovial sarcoma remains
unknown.
It is estimated that there are approximately 2000 patients in
the United States and Europe with MRCLS each year. MRCLS has a peak
incidence of occurrence in patients who are 30 to 50 years of age
and it typically follows a more aggressive course than other
liposarcomas. MRCLS also exhibits a unique metastatic pattern
arising first in the proximal areas of the extremities and
typically spreading to the bones (particularly the spine), serosal
surfaces, retroperitoneum, abdomen, pelvis, as well as to other
soft tissues. This metastatic pattern is different from the
characteristic pulmonary spread exhibited by synovial sarcoma.
Conference Call Information:The company will
host a live teleconference and webcast today at 8:00 a.m. EDT
(12:00 p.m. GMT) at which time management will provide a business
update, including these recent clinical data, and discuss financial
results for the Fourth Quarter / Full Year 2017. The press release
and the live webcast of the conference call will be available in
the investor section of Adaptimmune’s corporate website at
www.adaptimmune.com. An archive will be available after the call at
the same address.
To participate in the live conference call, if preferred, please
dial 1-800-239-9838 (U.S.) or 44(0)330 336 9411 or 0800 279 7204
(United Kingdom). After placing the call, please ask to be
joined into the Adaptimmune conference call and provide the
confirmation code (5199507).
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company
focused on the development of novel cancer immunotherapy products.
The Company’s unique SPEAR (Specific Peptide Enhanced Affinity
Receptor) T‑cell platform enables the engineering of T-cells to
target and destroy cancer, including solid tumors. Adaptimmune is
currently conducting clinical trials with SPEAR T-cells targeting
MAGE-A4, -A10, and AFP across several solid tumor
indications. GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK)
exercised its option to exclusively license the right to research,
develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell
therapy program in September 2017. Transition of this program
to GSK is ongoing. The Company is located in Philadelphia, USA
and Oxfordshire, U.K. For more information, please visit
http://www.adaptimmune.com
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (SEC)
on November 2, 2017, and our other SEC filings. The forward-looking
statements contained in this press release speak only as of the
date the statements were made and we do not undertake any
obligation to update such forward‑looking statements to reflect
subsequent events or circumstances.
Adaptimmune Contacts:
Media Relations:Sébastien Desprez – VP,
Communications and Investor RelationsT: +44 1235 430 583M: +44 7718
453 176 Sebastien.Desprez@adaptimmune.com
Investor Relations: Juli P. Miller, Ph.D. –
Director, Investor RelationsT: +1 215 825 9310M: +1 215 460
8920Juli.Miller@adaptimmune.com
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024